

Prescribing Clinical Network

Policy Statement	Alimemazine for the treatment of Urticaria in children (over 2 years of age) & adults
Policy Number	PCN 348-2018
Date of Issue	July - 2018
Review Date:	July - 2021 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
Recommendations: <p>The PCN does not recommend Alimemazine for the treatment of Urticaria in children (over the age of 2 years) and adults</p> <p>Alimemazine will be considered BLACK, for new patients, on the traffic light system</p> <p>Patients whose treatment with Alimemazine was initiated by the NHS before this recommendation was made, must be reviewed by their prescriber within 6-12 months, but should be able to continue treatment until, the patient and their NHS consultant consider it appropriate to stop.</p>	
Key Considerations: <ul style="list-style-type: none"> Limited objective evidence available to demonstrate any benefit for patients. Not a cost effective use of NHS resources given the significant list price increase. Safety concerns were noted by PCN members with regards first generation H1 antihistamines. 	
Date taken to Prescribing Clinical Network	4 th July 2018
Agreed by PCN members	13 th July 2018

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG